Description
Bcr-abl Inhibitor II is a cell-permeable thiadiazole compound that acts as an ATP binding site-targeting inhibitor of c-Abl and c-Src (SRC kinases) (K:i:= 44 and 354 nM, respectively). Bcr-abl Inhibitor II effectively inhibits cellular Bcr-abl Tyr245 phosphorylation and the clonogenic activity of Bcr-abl-transformed 32D cells, regardless of their resistance to Imatinib/STI571